CVnor5 mg

CVnor 5 mg is a long-acting dihydropyridine calcium-channel blocker prescribed to manage high blood pressure and several forms of chest pain (angina). It works by relaxing blood vessels, which lowers blood pressure and reduces the heart's workload. Below are the main clinical indications of CVnor 5 mg.

1. Hypertension (High Blood Pressure)

CVnor 5 mg is widely used as a first-line treatment for essential hypertension. It is effective when taken alone (monotherapy) and can also be combined with other antihypertensive medicines such as ACE inhibitors, ARBs, or diuretics for patients who need more aggressive blood pressure control.

2. Chronic Stable Angina

CVnor 5 mg is indicated for chronic stable angina pectoris, a type of chest pain that occurs predictably during physical exertion or stress due to reduced blood flow to the heart muscle. It can be used alone or alongside other anti-anginal drugs such as beta-blockers or nitrates.

3. Vasospastic (Prinzmetal's) Angina

CVnor 5 mg is also indicated for confirmed or suspected vasospastic angina, a form of chest pain caused by sudden spasm of the coronary arteries rather than blockage. By relaxing coronary artery smooth muscle, CVnor 5 mg helps prevent these spasms.

CVnor 5 mg should only be taken under the supervision of a registered physician. Self-medication for cardiovascular conditions can be dangerous.

CVnor 5 mg belongs to the Calcium-Channel Blockers (CCBs) class, specifically the dihydropyridine subgroup, which primarily targets vascular smooth muscle to produce vasodilation.

CVnor 5 mg belongs to the dihydropyridine class of calcium-channel blockers (CCBs). It selectively inhibits the influx of calcium ions across the cell membranes of vascular smooth muscle and, to a lesser extent, cardiac muscle.

• Vasodilation: By blocking calcium entry into vascular smooth muscle cells, CVnor 5 mg relaxes and widens blood vessels, particularly peripheral arterioles.
• Reduced peripheral resistance: Vasodilation lowers systemic vascular resistance, which directly reduces blood pressure and cardiac afterload.
• Improved coronary blood flow: CVnor 5 mg dilates coronary arteries and arterioles, increasing oxygen delivery to the heart muscle — important for patients with angina.
• Minimal reflex tachycardia: Unlike some short-acting calcium-channel blockers, CVnor 5 mg's gradual onset produces little to no reflex increase in heart rate.
• Long duration of action: CVnor 5 mg has a long elimination half-life (approximately 30–50 hours), allowing effective once-daily dosing and smooth, sustained blood pressure control.

The overall pharmacological effect is increased myocardial oxygen supply, improved cardiac output, and sustained reduction of blood pressure with a low incidence of abrupt hemodynamic changes.

Potentially Hazardous Interaction

In patients with markedly impaired left ventricular (cardiac) function, combining CVnor 5 mg with beta-blockers should be avoided, as data on this combination in such patients is limited, similar to precautions taken with other calcium-channel blockers.

Other Notable Interactions

• Digoxin: Clinical studies in healthy volunteers found no significant interaction between CVnor 5 mg and digoxin.
• Cimetidine: No clinically significant interaction was observed between CVnor 5 mg and cimetidine.
• Warfarin: CVnor 5 mg does not significantly alter the effect of warfarin on prothrombin time in healthy volunteers.
• Food: Food does not affect the rate or extent of CVnor 5 mg absorption, so it can be taken with or without meals.
• CYP3A4 inhibitors (general note): As CVnor 5 mg is metabolized via the liver, strong CYP3A4 inhibitors (such as certain antifungals or protease inhibitors) may increase CVnor 5 mg plasma concentration; dose adjustment or monitoring may be needed.

Always inform your doctor or pharmacist about all medicines, supplements, and herbal products you are currently taking before starting CVnor 5 mg.

Most side effects of CVnor 5 mg are related to its vasodilatory action and are generally mild to moderate. Common and less common effects include:

Common Side Effects

• Dizziness or lightheadedness
• Facial flushing
• Headache
• Low blood pressure (hypotension)
• Peripheral edema (swelling of ankles or feet)

Less Common Side Effects

• Gastrointestinal disturbances (nausea, abdominal discomfort)
• Increased frequency of urination
• Fatigue or lethargy
• Eye pain or visual disturbance
• Mood changes, including mental depression
• Rash and fever due to hypersensitivity reactions
• Abnormal liver function tests (rare)

Rare but Serious Effects

At the start of treatment, a paradoxical worsening of chest pain (ischaemic chest pain) may occasionally occur. In rare cases, an excessive fall in blood pressure has been associated with transient blindness or reduced blood flow to the heart or brain. Seek immediate medical attention if you experience fainting, severe chest pain, or sudden vision changes while on CVnor 5 mg.

Pregnancy

CVnor 5 mg is classified as Pregnancy Category C. There are no adequate, well-controlled studies confirming its safety in pregnant women. It should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the developing fetus. Pregnant patients or those planning pregnancy should discuss safer alternatives with their doctor.

Breastfeeding

It is not known whether CVnor 5 mg passes into human breast milk. As a precaution, breastfeeding is generally not recommended while taking CVnor 5 mg unless advised otherwise by a physician.

• Use with caution in patients with hepatic (liver) impairment, as CVnor 5 mg is metabolized in the liver and its effects may be prolonged.
• Use with caution during pregnancy and breastfeeding (see Pregnancy & Lactation section).
• Patients with severe aortic stenosis should be monitored closely, as excessive vasodilation could worsen symptoms.
• Since CVnor 5 mg can cause dizziness, patients should be cautious when driving or operating heavy machinery, especially when starting treatment.
• Do not discontinue CVnor 5 mg abruptly without medical advice, particularly in patients with angina.

Symptoms of Overdose

CVnor 5 mg overdose can cause excessive peripheral vasodilation and reflex tachycardia (rapid heartbeat). Severe cases may lead to marked, prolonged low blood pressure that can progress to shock, which has been reported to be fatal in rare instances.

Management of Overdose

• Immediate active cardiovascular support, including continuous monitoring of heart and lung function
• Elevation of the extremities to help maintain blood flow to vital organs
• Careful management of circulating fluid volume and monitoring of urine output
• Vasoconstrictor medications may be used to restore vascular tone and blood pressure, if not contraindicated
• Intravenous calcium gluconate may help reverse the effects of calcium-channel blockade
• Gastric lavage may be considered in select cases
• Activated charcoal, if given within 2 hours of ingestion, can reduce further absorption of CVnor 5 mg
• Because CVnor 5 mg is highly protein-bound, dialysis is unlikely to be effective in removing it from the body

If an overdose is suspected, seek emergency medical care immediately.

• Store in a cool and dry place, away from direct light
• Keep the medicine at room temperature, avoiding excess heat or moisture
• Keep all medicines, including CVnor 5 mg, out of reach of children
• Do not use after the expiry date printed on the packaging

Children (6 to 17 years) with Hypertension

The recommended starting dose is 2.5 mg once daily, which may be increased to 5 mg once daily if the target blood pressure is not achieved after 4 weeks. Doses above 5 mg daily have not been studied in pediatric patients.

Children Under 6 Years

The safety and blood-pressure-lowering effect of CVnor 5 mg in children under 6 years of age have not been established.

Elderly Patients

CVnor 5 mg is equally well tolerated at similar doses in elderly and younger patients. Standard dosing is generally recommended, but dose increases should be made cautiously and under close monitoring.

Renal Impairment

CVnor 5 mg plasma concentration does not correlate strongly with the degree of renal impairment, so normal dosing is typically recommended. CVnor 5 mg is not removed by dialysis.

Hepatic Impairment

Specific dosage guidelines for mild-to-moderate hepatic impairment have not been firmly established; treatment should start at the lower end of the dosing range. In severe hepatic impairment, CVnor 5 mg should be initiated at 2.5 mg once daily and titrated slowly under medical supervision.